key: cord-0297589-dpwra9go
authors: Guan, J.; Xi, A.; Jin, D.; Mou, X.; Xu, Z.
title: Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis
date: 2022-01-10
journal: nan
DOI: 10.1101/2022.01.07.22268878
sha: 09f80c076f52230faf0426f8a07c5fbbc6d0c2c5
doc_id: 297589
cord_uid: dpwra9go

Objective: We performed a meta analysis in order to determine safety of granulocyte macrophage colony stimulating factor (GM CSF) antibodies on COVID 19. Methods: We searched from the Cochrane Library, PubMed, Embase, biorxiv and medrxiv databases beginning in the COVID-19 outbreak on December 1, 2019 until August 29, 2021. The primary outcomes included death, the incidence of invasive mechanical ventilation (IMV), ventilation requirement, and secondary infection. Results: 6 eligible literature involving 1501 COVID 19 patients were recruited, and they were divided into experimental group (n = 736) and control group (n = 765). Using a random effect model, we found that the GM CSF antibodies treatment was associated with a 3.8-26.9% decline of the risk of mortality[odd ratio (OR) = 0.06, 95% confidence interval (CI): -0.11, -0.01, p =0.02], a 5.3-28.7% reduction of incidence of IMV [OR = 0.51, 95% CI: 0.28, 0.95, p =0.03], and a 23.3-50.0% enhancement of ventilation improvement [OR = 11.70, 95% CI: 1.99, 68.68, p=0.006]. There were no statistically significant differences in the association between two groups in second infection. Conclusion: Severe COVID 19 patients may benefit from GM CSF antibodies.

The COVID-19 pandemic is still threatening public health by its serious outcomes and 32 strong infectivity The classic symptoms of COVID-19 include high fever, respiratory failure, 33 and even acute respiratory distress syndrome (ARDS). Granulocyte-macrophage 34 colony-stimulating factor (GM-CSF) antibodies inhibiting GM-CSF signaling axis by 35 targeting GM-CSF, such as Gimsilumab, lenzilumab, namilumab, and otilimab, or GM-CSF the treatment of COVID-19. However, their underlying pharmacological mechanisms, safety, 45 and adverse events in the treatment of COVID-19 have not been clearly clarified. In addition, 46 the safety and efficacy of GM-CSF antibodies in the treatment of COVID-19 are also 47 controversial; in particular, mortality, drug use, and secondary infections should be of 48 concern 4-6 . Therefore, the present meta-analysis was conducted to investigate GM-CSF 49 antibody treatment in COVID-19 patients.

This study conducted according to the Preferred Reporting Items for Systematic reviews 52 and Meta-Analyses (PRISMA) and registered in PROSPERO (CRD42020221450; 53 https://www.crd.york.ac.uk/prospero/). ("SARS-CoV-2" OR "coronavirus" OR "nCoV" OR "pneumonia" OR "corona-virus" OR 69 "2019nCoV" OR "COVID-19") AND ("lenzilumab" OR "TJM" OR "recombinant 70 monoclonal antibodies against granulocyte macrophage colony-stimulating factor" OR 71 "monoclonal antibodies against granulocyte macrophage colony-stimulating factor" OR 72 "antibodies against granulocyte macrophage colony-stimulating factor" OR "mavrilimumab" 73 OR "Otilimab" OR "TJ003234" OR "Roivant" OR "MOR103" OR "kb003" OR 74 "plonmarlimab" OR "granulocyte macrophage colony stimulating factor" OR "GM-CSF" OR 75 "CSF"). Of note, preprint results from registered clinical trials were also included. a random-effects model (Mantel-Haenszel method) was employed for the meta-analysis. 90 Heterogeneity among studies was evaluated by χ 2 , I 2 , df, and Tau 2 . Negative I 2 values were 91 set to zero. 25%, 50%, and 75% I 2 indicated a low, moderate, and high heterogeneity, 92 respectively. Publication bias was assessed by using funnel plots and Egger's asymmetry test. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268878 doi: medRxiv preprint Following the searching strategy described in Figure Two of included studies were nonrandomized studies and the other four were RCTs. 109 Characteristics of the included studies were summarized in Table 1 , including the study 110 design (type of study), population, treatment methods, sample sizes, age, gender, standard of 111 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. should be a concern. Therefore, our primary analysis provided consistent results across most 202 analyses. Although adjustments for potential confounders were performed in our study, some 203 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. COVID-19 is limited. Besides, our study had some limitations since two observational 235 studies were included; potential biases and confounding factors could not be excluded. 236 Therefore, more RCTs and high-quality literature is required to validate our study. Especially, 237 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268878 doi: medRxiv preprint several medications in the past have been highlighted and even received emergency approvals 238 based on flawed studies in the age of COVID-19, which may ultimately lead to drug 239 shortages for patients who really need those medications. 

GM-CSF-based treatments in COVID-19: reconciling opposing 273 therapeutic approaches

Mavrilimumab for severe COVID-19

Pharmaco-Immunomodulatory Therapy in COVID-19

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

GM-CSF blockade with mavrilimumab in severe COVID-19 281 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

E465-E473. (ClinicalTrials.gov, NCT04318366)

GM-CSF Neutralization with lenzilumab in severe COVID-19 284 pneumonia: a case-cohort study

A Randomized Trial of Otilimab in Severe

Namilumab or infliximab compared to standard of care in hospitalised 290 patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial

Mavrilimumab in patients with severe COVID-19 pneumonia and 293 systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind

Lenzilumab efficacy and safety in newly hospitalized Covid-19 297 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial

IL-3, and IL-5 Family of Cytokines: Regulators of 301 Inflammation

FDA approves emergency IND use of Humanigen's lenzilumab for compassionate

COVID-19 patients

COVID-19 associated chronic ARDS successfully treated with 307 lenzilumab

Tocilizumab for severe worsening COVID-19 pneumonia: a 309 propensity score analysis

 249 The authors declare that there is no conflict of interest. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268878 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.07.22268878 doi: medRxiv preprint